Travere Therapeutics, Inc. Net Income Loss

• Travere Therapeutics, Inc. showed an increase of +92.1% in Net Income Loss from 2024 to 2025.
• This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
• XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2011 to 2025), Travere Therapeutics, Inc.'s Net Income Loss has declined by 110,863.4%.
• Historical annual values: Fiscal year 2025: -$25.55 million | Fiscal year 2024: -$321.55 million | Fiscal year 2023: -$111.40 million | Fiscal year 2022: -$278.48 million | Fiscal year 2021: -$180.09 million | Fiscal year 2020: -$169.43 million | Fiscal year 2019: -$146.43 million | Fiscal year 2018: -$102.68 million | Fiscal year 2017: -$59.73 million | Fiscal year 2016: -$47.90 million | Fiscal year 2015: $117.24 million | Fiscal year 2014: -$110.94 million | Fiscal year 2013: -$34.63 million | Fiscal year 2012: -$30.34 million | Fiscal year 2012: -$14.8 thousand | Fiscal year 2011: -$23.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026